Highlights
Predictive Value of OxPL-apoB
In patients with a recent acute coronary syndrome (ACS) receiving optimized statin therapy, elevated levels of oxidized phospholipids on apolipoprotein B-100 (OxPL-apoB) are a significant predictor of major adverse cardiovascular events (MACE).
Impact of PCSK9 Inhibition
Alirocumab treatment significantly reduced median OxPL-apoB levels by 13.0% and Lp(a) levels by 26.2% compared to placebo, effectively neutralizing the associated cardiovascular risk.
Lp(a) and OxPL Interaction
The study identified a critical three-way interaction: OxPL-apoB is a particularly potent independent predictor of MACE when Lipoprotein(a) levels are relatively low, suggesting a nuanced role for inflammation in residual risk.
Introduction: The Pro-inflammatory Burden of Residual Risk
Despite the widespread use of intensive statin therapy, patients who have survived an acute coronary syndrome (ACS) remain at high risk for recurrent ischemic events. This residual risk is increasingly attributed to pathways beyond low-density lipoprotein cholesterol (LDL-C), specifically inflammation and elevated Lipoprotein(a) [Lp(a)]. Lp(a) is a unique lipoprotein particle consisting of an LDL-like particle with an additional protein, apolipoprotein(a), covalently bound to apolipoprotein B-100 (apoB).
One of the most biologically active components of Lp(a) is its content of oxidized phospholipids (OxPL). OxPL-apoB reflects the pro-inflammatory and pro-atherogenic properties of these lipoproteins. While the association between Lp(a) and cardiovascular disease is well-established, the specific role of its oxidized phospholipid cargo in the modern era of PCSK9 inhibition—and its predictive value following an acute event—has remained unclear. The ODYSSEY OUTCOMES trial provided a unique opportunity to evaluate these biomarkers in a high-risk population.
Study Design: Insights from the ODYSSEY OUTCOMES Trial
This study was a pre-specified secondary analysis of the ODYSSEY OUTCOMES trial, a multicenter, randomized, double-blind, placebo-controlled investigation. The trial enrolled 11,630 participants who had experienced an ACS within 1 to 12 months prior to randomization and were receiving intensive or maximum-tolerated statin therapy.
Participants were randomized to receive either alirocumab (75 or 150 mg every 2 weeks) or a matching placebo. The primary endpoint was the occurrence of major adverse cardiovascular events (MACE), a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. OxPL-apoB and Lp(a) levels were measured at baseline and again 4 months after randomization in a subset of 5,185 participants. The researchers employed proportional hazards models, adjusted for baseline covariates, to evaluate the association between log2-transformed biomarker levels and MACE.
Key Findings: OxPL-apoB as a Predictor of MACE
Over a median follow-up of 2.9 years, the study yielded several critical insights into the relationship between lipid-driven inflammation and clinical outcomes.
Biomarker Reduction by Alirocumab
Alirocumab demonstrated a potent effect on both biomarkers. Compared to the placebo group, alirocumab reduced median OxPL-apoB levels by 13.0% and Lp(a) levels by 26.2% (P < 0.0001 for both). This confirms that PCSK9 inhibition not only lowers LDL-C but also significantly impacts the levels of pro-inflammatory lipoproteins circulating in the blood.
Baseline Risk in the Placebo Group
In patients receiving placebo (standard of care with statins), OxPL-apoB was a clear indicator of risk. A doubling of baseline OxPL-apoB levels was associated with a hazard ratio (HR) of 1.081 (95% CI, 1.026–1.139; P = 0.0034) for MACE. This finding underscores the fact that even with optimized statin therapy, the inflammatory burden carried by apoB-containing lipoproteins continues to drive adverse outcomes.
The Lp(a) Dominance and Interaction
When Lp(a) levels were added to the statistical model, the direct association between OxPL-apoB and MACE in the overall placebo group became non-significant. This suggests that the risk attributed to OxPL-apoB is largely captured by the Lp(a) measurement itself, as Lp(a) is the primary carrier of these oxidized lipids. However, a significant three-way interaction was discovered between continuous OxPL-apoB, Lp(a) levels (stratified at the median), and treatment group (P-interaction = 0.0023).
In the placebo group, OxPL-apoB was a significant predictor of MACE specifically when Lp(a) levels were below the median. Conversely, when Lp(a) was already high, the additional predictive value of OxPL-apoB was diminished. This suggests that in patients with lower Lp(a), the “quality” or inflammatory state of the apoB particles (represented by OxPL) becomes a dominant risk factor.
Clinical Implications and Treatment Abrogation
Perhaps the most clinically relevant finding was that in the alirocumab group, neither OxPL-apoB nor Lp(a) remained significantly associated with the risk of MACE. The hazard ratios for these biomarkers effectively dropped to unity. This implies that the administration of a PCSK9 inhibitor like alirocumab “abrogates” or neutralizes the risk associated with these pro-inflammatory markers.
This neutralization may occur through two mechanisms: first, the absolute reduction in the number of particles carrying OxPL, and second, the profound lowering of LDL-C, which may change the overall atherogenic environment such that the residual inflammatory signals from OxPL are no longer sufficient to trigger clinical events.
Expert Commentary and Mechanistic Insights
From a mechanistic perspective, OxPLs are known to be sequestered on the apo(a) component of Lp(a). These phospholipids are highly reactive and promote endothelial dysfunction, monocyte recruitment, and the transformation of macrophages into foam cells within the arterial wall. By measuring OxPL-apoB, clinicians are essentially measuring the “inflammatory payload” of the atherogenic lipoprotein profile.
The fact that OxPL-apoB predicts risk primarily when Lp(a) is low is particularly intriguing. It suggests that in the absence of high Lp(a) concentrations, other apoB-containing particles (such as LDL or VLDL) may carry enough OxPL to contribute to the progression of atherosclerosis and the precipitation of ACS. Alirocumab’s ability to disconnect these biomarkers from clinical outcomes provides a strong rationale for its use in high-risk post-ACS patients, regardless of their baseline Lp(a) or OxPL status.
However, it should be noted that while alirocumab reduces these levels, it does not eliminate them. Targeted therapies specifically designed to lower Lp(a) by 80-90% (such as antisense oligonucleotides or siRNA) are currently in Phase 3 trials. These upcoming data will help clarify whether further reducing the OxPL burden can yield even greater cardiovascular benefits than those seen with PCSK9 inhibitors.
Conclusion
In summary, the ODYSSEY OUTCOMES analysis demonstrates that OxPL-apoB is a valuable biomarker for identifying residual inflammatory risk in ACS patients on optimized statin therapy. While its risk is closely tied to Lp(a), its independent predictive power in patients with lower Lp(a) levels highlights a previously underappreciated facet of cardiovascular risk. Most importantly, the study confirms that PCSK9 inhibition with alirocumab effectively mitigates the risk associated with these particles, providing a robust therapeutic strategy for secondary prevention.
Funding and Clinical Trial Information
The ODYSSEY OUTCOMES trial was funded by Sanofi and Regeneron Pharmaceuticals, Inc.
ClinicalTrials.gov Identifiers: NCT01663402 and NCT00001747.
References
1. Tsimikas S, et al. Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes After Acute Coronary Syndrome. Circulation. 2025;152(24):1666-1678.
2. Schwartz GG, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379:2097-2107.
3. Bittner VA, et al. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Outcomes After Acute Coronary Syndrome. J Am Coll Cardiol. 2020;75(2):133-144.
